---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-22-000092"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2022-10-17T23:59:59+00:00"
generated_at: "2026-06-23T03:12:07.416471+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MacroGenics and Gilead sign $60M upfront option deal for MGD024 and two bispecific programs

## Summary
- Upfront $60M from Gilead; potential milestones up to $1.7B for MGD024 and two research programs.
- Gilead gets exclusive option to license MGD024 (Phase 1 CD123×CD3 DART) for AML and MDS.
- MacroGenics to continue Phase 1 study; Gilead may exercise option at predefined decision points.
- Tiered double-digit royalties on MGD024 net sales; flat royalties on products from two research programs.

## SEC filing metadata
- accession: 0001125345-22-000092
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2022-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534522000092/0001125345-22-000092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534522000092/mgnx-20221017.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-22-000092
- JSON: https://secwatch.observer/filing/0001125345-22-000092.json
- Plain text: https://secwatch.observer/filing/0001125345-22-000092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.